CONQUER

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

• Phentermine (norepinephrine releasing agent) + Topiramate (GABA receptor modulator) is FDA approved for chronic weight management. (FDA, 2012)

• Common side effects of Qsymia™ include nausea, constipation, headaches, vomiting, and dizziness.

• Women of child-bearing potential should have a negative pregnancy test prior to initiation. Teratogenic effect — cleft lip

Infographic

Reference

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Apr 16;377(9774):1341-52. doi: 10.1016/S0140-6736(11)60205-5. Epub 2011 Apr 8. Erratum in: Lancet. 2011 Apr 30;377(9776):1494.

>